BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176. [PMID: 22262022 DOI: 10.1159/000335597] [Cited by in Crossref: 525] [Cited by in F6Publishing: 416] [Article Influence: 58.3] [Reference Citation Analysis]
Number Citing Articles
1 Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941-960. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
2 Nonaka D, Papaxoinis G, Mansoor W. Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumors. American Journal of Surgical Pathology 2016;40:738-44. [DOI: 10.1097/pas.0000000000000621] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
3 Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, Yang K, Zhang X. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study. Front Pharmacol 2021;12:624534. [PMID: 33986664 DOI: 10.3389/fphar.2021.624534] [Reference Citation Analysis]
4 Gangi A, Howe JR. The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol 2020;27:3270-80. [PMID: 32632880 DOI: 10.1245/s10434-020-08787-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
6 Laird AM, Libutti SK. Management of Other Gastric and Duodenal Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:253-66. [PMID: 32151359 DOI: 10.1016/j.soc.2019.11.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Semin Nucl Med. 2016;46:225-238. [PMID: 27067503 DOI: 10.1053/j.semnuclmed.2015.12.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
8 Spolverato G, Bagante F, Wagner D, Buettner S, Gupta R, Kim Y, Maqsood H, Pawlik TM. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198:155-164. [PMID: 26095419 DOI: 10.1016/j.jss.2015.05.048] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
9 Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015;44:181-189. [PMID: 25479584 DOI: 10.1097/mpa] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Bernard V, Lombard-bohas C, Taquet M, Caroli-bosc F, Ruszniewski P, Niccoli P, Guimbaud R, Chougnet CN, Goichot B, Rohmer V, Borson-chazot F, Baudin E, _ _. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. European Journal of Endocrinology 2013;168:665-74. [DOI: 10.1530/eje-12-1101] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
11 Viúdez A, De Jesus-Acosta A, Carvalho FL, Vera R, Martín-Algarra S, Ramírez N. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. Crit Rev Oncol Hematol 2016;101:193-206. [PMID: 27021395 DOI: 10.1016/j.critrevonc.2016.03.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
12 Loree JM, Hiruki T, Kennecke HF. Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases. Case Rep Oncol 2016;9:76-82. [PMID: 26933423 DOI: 10.1159/000443985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E. Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. Nat Rev Clin Oncol 2016;13:537-49. [DOI: 10.1038/nrclinonc.2016.37] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
14 Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson F, Seban RD, Chougnet CN, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. Abdom Radiol (NY) 2019;44:2474-93. [PMID: 30980115 DOI: 10.1007/s00261-019-01994-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Norlén O, Montan H, Hellman P, Stålberg P, Sundin A. Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. World J Surg 2018;42:498-505. [PMID: 29159606 DOI: 10.1007/s00268-017-4364-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
16 Shin WY, Lee KY, Ahn SI, Park SY, Park KM. Cutaneous metastasis as an initial presentation of a non-functioning pancreatic neuroendocrine tumor. World J Gastroenterol 2015; 21(33): 9822-9826 [PMID: 26361431 DOI: 10.3748/wjg.v21.i33.9822] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Giustina A, Mazziotti G, Maffezzoni F, Amoroso V, Berruti A. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opinion on Investigational Drugs 2014;23:1619-35. [DOI: 10.1517/13543784.2014.942728] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
18 Böning G, Kahn JF, Kaul D, Rotzinger R, Freyhardt P, Pavel M, Streitparth F. CT follow-up in patients with neuroendocrine tumors (NETs): combined radiation and contrast dose reduction. Acta Radiol 2018;59:517-26. [PMID: 28786299 DOI: 10.1177/0284185117726101] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Hwang HS, Kim Y, An S, Kim SJ, Kim JY, Kim SY, Hwang DW, Park DH, Lee SS, Kim SC, Seo DW, Hong SM. Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound-Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated. Pancreas 2018;47:1296-303. [PMID: 30211805 DOI: 10.1097/MPA.0000000000001157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
20 Kennedy AS. Hepatic-directed Therapies in Patients with Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:193-207. [PMID: 26614377 DOI: 10.1016/j.hoc.2015.09.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
21 Denecke T, Baur AD, Ihm C, Steffen IG, Tischer E, Arsenic R, Pascher A, Wiedenmann B, Pavel M. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors. European Journal of Radiology 2013;82:e550-5. [DOI: 10.1016/j.ejrad.2013.06.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
22 D’Haese JG, Tosolini C, Ceyhan GO, Kong B, Esposito I, Michalski CW, Kleeff J. Update on surgical treatment of pancreatic neuroendocrine neoplasms. World J Gastroenterol 2014; 20(38): 13893-13898 [PMID: 25320524 DOI: 10.3748/wjg.v20.i38.13893] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
23 Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105:1176-1181. [PMID: 24975505 DOI: 10.1111/cas.12473] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 16.0] [Reference Citation Analysis]
24 Martínez J, Besa S, Arab JP, Quintana JC, Regonesi C, Huete A, Jarufe N, Guerra JF, Benítez C, Arrese M. Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. Annals of Hepatology 2015;14:752-5. [DOI: 10.1016/s1665-2681(19)30772-0] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Guo J, Zhang Q, Bi X, Zhou J, Li Z, Huang Z, Zhang Y, Li M, Chen X, Hu X, Yihebali C, Liang J, Liu J, Zhao J, Cai J, Zhao H. Systematic review of resecting primary tumor in MNETs patients with unresectable liver metastases. Oncotarget 2017;8:17396-405. [PMID: 28030811 DOI: 10.18632/oncotarget.14156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
26 Mohanty SK, Tiwari A, Bhardwaj N, Chuang F, Kim E, Lugo H, Yuan X, Diffalha SA, Peralta-Venturina M, Balzer B, Dhall D. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours. J Clin Pathol 2021;74:582-8. [PMID: 32934105 DOI: 10.1136/jclinpath-2020-206645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92:135-81. [PMID: 23645327 DOI: 10.1097/MD.0b013e3182954af1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 54] [Article Influence: 13.9] [Reference Citation Analysis]
28 Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, Hwang W, Sze DY, Kothary N, Stashek K, Wileyto EP, Salem R, Metz DC, Soulen MC. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival. Cardiovasc Intervent Radiol. 2017;40:69-80. [PMID: 27738818 DOI: 10.1007/s00270-016-1478-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
29 Briest F, Grabowski P. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treat Rev 2015;41:423-30. [PMID: 25837868 DOI: 10.1016/j.ctrv.2015.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
30 Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. Biomed Res Int 2015;2015:917968. [PMID: 25879040 DOI: 10.1155/2015/917968] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
31 de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, Berdelou A, Leboulleux S, Elias D, Baudin E. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172:R151-R166. [PMID: 25385817 DOI: 10.1530/eje-14-0630] [Cited by in Crossref: 59] [Cited by in F6Publishing: 26] [Article Influence: 8.4] [Reference Citation Analysis]
32 Moris D, Tsilimigras DI, Chakedis J, Beal EW, Felekouras E, Vernadakis S, Schizas D, Fung JJ, Pawlik TM. Liver transplantation for unresectable colorectal liver metastases: A systematic review. J Surg Oncol. 2017;116:288-297. [PMID: 28513862 DOI: 10.1002/jso.24671] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
33 Woodbridge LR, Murtagh BM, Yu DFQC, Planche KL. Midgut Neuroendocrine Tumors: Imaging Assessment for Surgical Resection. RadioGraphics 2014;34:413-26. [DOI: 10.1148/rg.342135504] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
34 Yokode M, Itai R, Yamashita Y, Zen Y. A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation? Medicine (Baltimore) 2017;96:e8534. [PMID: 29137060 DOI: 10.1097/MD.0000000000008534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
35 Kessler J, Singh G, Ituarte PHG, Allen R, Chang S, Li D. A Comparison of Liver-Directed Therapy and Systemic Therapy for the Treatment of Liver Metastases in Patients with Gastrointestinal Neuroendocrine Tumors: Analysis of the California Cancer Registry. J Vasc Interv Radiol 2021;32:393-402. [PMID: 33358144 DOI: 10.1016/j.jvir.2020.10.019] [Reference Citation Analysis]
36 Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:705-717. [PMID: 23582914 DOI: 10.1016/j.bpg.2013.01.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
37 Keutgen XM, Nilubol N, Glanville J, Sadowski SM, Liewehr DJ, Venzon DJ, Steinberg SM, Kebebew E. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159:311-318. [PMID: 26453135 DOI: 10.1016/j.surg.2015.05.042] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
38 Pickens RC, Sulzer JK, Passeri MJ, Murphy K, Vrochides D, Martinie JB, Baker EH, Ocuin LM, McKillop IH, Iannitti DA. Operative Microwave Ablation for the Multimodal Treatment of Neuroendocrine Liver Metastases. J Laparoendosc Adv Surg Tech A 2021;31:917-25. [PMID: 33296283 DOI: 10.1089/lap.2020.0558] [Reference Citation Analysis]
39 Hori T, Takaori K, Uemoto S. Pancreatic neuroendocrine tumor accompanied with multiple liver metastases. World J Hepatol 2014; 6(8): 596-600 [PMID: 25232452 DOI: 10.4254/wjh.v6.i8.596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
40 Hayoz R, Vietti-Violi N, Duran R, Knebel JF, Ledoux JB, Dromain C. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor.Eur Radiol. 2020;30:6593-6602. [PMID: 32601948 DOI: 10.1007/s00330-020-06930-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
41 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 16.3] [Reference Citation Analysis]
42 Rossi RE, Burroughs AK, Caplin ME. Liver transplantation for unresectable neuroendocrine tumor liver metastases. Ann Surg Oncol. 2014;21:2398-2405. [PMID: 24562931 DOI: 10.1245/s10434-014-3523-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
43 Naalla R, Konchada K, Kannappan O, Lingadakai R. Duodenal carcinoid with carcinoid syndrome. BMJ Case Rep. 2014;2014:pii: bcr2013202159. [PMID: 24414187 DOI: 10.1136/bcr-2013-202159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
44 Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Zarghampour M, Khoshpouri P, Ameli S, Li Z, Hu D, Kamel IR. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol 2019;29:5160-71. [DOI: 10.1007/s00330-019-06100-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Dhir M, Shrestha R, Steel JL, Marsh JW, Tsung A, Tublin ME, Amesur NB, Orons PD, Santos E, Geller DA. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience. Ann Surg Oncol 2017;24:450-9. [DOI: 10.1245/s10434-016-5591-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
46 Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 2016;3:203-19. [PMID: 30338051 DOI: 10.2217/ije-2016-0006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
47 Bartsch DK, Albers MB. Controversies in surgery for multiple endocrine neoplasia type 1-associated Zollinger–Ellison syndrome. International Journal of Endocrine Oncology 2015;2:263-71. [DOI: 10.2217/ije.15.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
48 Wang Y, Jin K, Tan H, Zhang P, Yang Q, Wang W, Li J, Shao C, Xue L, Feng S, Chen M, Yu X, Chen J. Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol 2017;80:507-16. [DOI: 10.1007/s00280-017-3367-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
49 Solomou S, Khan R, Propper D, Berney D, Druce M. A case of insulin and ACTH co-secretion by a neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep 2014;2014:130082. [PMID: 24683485 DOI: 10.1530/EDM-13-0082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Robelin P, Hadoux J, Forestier J, Planchard D, Hervieu V, Berdelou A, Scoazec JY, Valette PJ, Leboulleux S, Ducreux M, Lombard-Bohas C, Baudin E, Walter T. Characterization, Prognosis, and Treatment of Patients With Metastatic Lung Carcinoid Tumors. J Thorac Oncol 2019;14:993-1002. [PMID: 30771520 DOI: 10.1016/j.jtho.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
51 Ye H, Xu HL, Shen Q, Zheng Q, Chen P. Palliative Resection of Primary Tumor in Metastatic Nonfunctioning Pancreatic Neuroendocrine Tumors. Journal of Surgical Research 2019;243:578-87. [DOI: 10.1016/j.jss.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
52 Rinke A, Krug S. Neuroendocrine tumours – Medical therapy: Biological. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:79-91. [DOI: 10.1016/j.beem.2015.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
53 Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Gaudio MD, Cucchetti A, Pinna AD. Liver transplantation for hepatic tumors: A systematic review. World J Gastroenterol 2014; 20(18): 5345-5352 [PMID: 24833864 DOI: 10.3748/wjg.v20.i18.5345] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
54 Barbier L, Neuzillet C, Dokmak S, Sauvanet A, Ruszniewski P, Belghiti J. Liver transplantation for metastatic neuroendocrine tumors. Hepat Oncol 2014;1:409-21. [PMID: 30190976 DOI: 10.2217/hep.14.21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Ronot M, Cuccioli F, Dioguardi Burgio M, Vullierme M, Hentic O, Ruszniewski P, d’Assignies G, Vilgrain V. Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location. European Journal of Radiology 2017;89:156-62. [DOI: 10.1016/j.ejrad.2017.02.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
56 Braat AJAT, Ahmadzadehfar H, Kappadath SC, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. Cardiovasc Intervent Radiol 2020;43:246-53. [PMID: 31646375 DOI: 10.1007/s00270-019-02350-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
57 Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 2021. [PMID: 34480724 DOI: 10.1007/s12020-021-02859-y] [Reference Citation Analysis]
58 Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E. Are we reproducible in measurement of NET liver metastasis? Digestive and Liver Disease 2017;49:1121-7. [DOI: 10.1016/j.dld.2017.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Chiorean L, Bartos A, Pelau D, Iancu D, Ciuleanu T, Buiga R, Oancea I, Mangrau A, Iancu C, Badea R. Neuroendocrine tumor of gallbladder with liver and retroperitoneal metastases and a good response to the chemotherapeutical treatment. J Med Ultrason (2001) 2015;42:271-6. [PMID: 26576584 DOI: 10.1007/s10396-014-0585-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Kim S, Pak K, Koo PJ, Kwak JJ, Chang S. The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis. Eur J Nucl Med Mol Imaging 2015;42:1964-70. [DOI: 10.1007/s00259-015-3155-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
61 Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. Best Pract Res Clin Endocrinol Metab 2016;30:45-57. [PMID: 26971843 DOI: 10.1016/j.beem.2016.01.003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
62 Severi S, Sansovini M, Ianniello A, Bodei L, Nicolini S, Ibrahim T, Di Iorio V, D’errico V, Caroli P, Monti M, Paganelli G. Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2015;42:1955-63. [DOI: 10.1007/s00259-015-3105-7] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
63 Rossi RE, Naik K, Navalkissoor S, Imber C, O'beirne J, Toumpanakis C, Caplin ME. Case Report of Multimodality Treatment for Metastatic Parathyroid Hormone-related Peptide-secreting Pancreatic Neuroendocrine Tumour. Tumori Journal 2018;100:e153-6. [DOI: 10.1177/1636.17936] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
64 Calissendorff J, Maret E, Sundin A, Falhammar H. Ileal neuroendocrine tumors and heart: not only valvular consequences. Endocrine 2015;48:743-55. [PMID: 25319177 DOI: 10.1007/s12020-014-0446-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
65 Marquez-medina D, Popat S. Systemic therapy for pulmonary carcinoids. Lung Cancer 2015;90:139-47. [DOI: 10.1016/j.lungcan.2015.08.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Powers BD, Rothermel LD, Fleming JB, Strosberg JR, Anaya DA. A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes. J Gastrointest Surg 2020;24:2773-9. [DOI: 10.1007/s11605-019-04433-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Davi MV, Pia A, Guarnotta V, Pizza G, Colao A, Faggiano A; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J Endocrinol Invest 2017;40:9-20. [PMID: 27624297 DOI: 10.1007/s40618-016-0536-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
68 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
69 Grozinsky-Glasberg S, Pavel M. Inhibition of mTOR in carcinoid tumors. Target Oncol 2012;7:189-95. [PMID: 22886906 DOI: 10.1007/s11523-012-0225-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
70 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
71 Tagai N, Goi T, Morikawa M, Kurebayashi H, Kato S, Fujimoto D, Koneri K, Murakami M, Hirono Y, Noriki S, Katayama K. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. Int Cancer Conf J 2017;6:175-9. [PMID: 31149497 DOI: 10.1007/s13691-017-0301-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
72 Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, Sue O'Dorisio M, O'Dorisio TM, Howe JR. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 2014;31:935-44. [PMID: 25241033 DOI: 10.1007/s10585-014-9681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
73 Passacantilli I, Capurso G, Archibugi L, Calabretta S, Caldarola S, Loreni F, Delle Fave G, Sette C. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget 2014;5:5381-91. [PMID: 25026292 DOI: 10.18632/oncotarget.2111] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
74 Özdirik B, Jann H, Bischoff P, Fehrenbach U, Tacke F, Roderburg C, Wiedenmann B. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. Medicine (Baltimore) 2021;100:e23835. [PMID: 33429744 DOI: 10.1097/MD.0000000000023835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Berardi R, Rinaldi S, Torniai M, Morgese F, Partelli S, Caramanti M, Onofri A, Polenta V, Pagliaretta S, Falconi M, Cascinu S. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy—A literature review. Critical Reviews in Oncology/Hematology 2016;98:264-74. [DOI: 10.1016/j.critrevonc.2015.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
76 Angelousi A, Koffas A, Grozinsky-Glasberg S, Gertner J, Kassi E, Alexandraki K, Caplin ME, Kaltsas G, Toumpanakis C. Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients. Pancreas 2019;48:934-42. [PMID: 31268974 DOI: 10.1097/MPA.0000000000001347] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
77 Mandair D, Khan MS, Lopes A, Furtado O’mahony L, Ensell L, Lowe H, Hartley JA, Toumpanakis C, Caplin M, Meyer T. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism 2021;106:872-82. [DOI: 10.1210/clinem/dgaa822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
78 Shinji S, Sasaki N, Yamada T, Koizumi M, Ohta R, Matsuda A, Yokoyama Y, Takahashi G, Hotta M, Hara K, Takeda K, Ueda K, Kuriyama S, Ishiwata T, Ueda Y, Murakami T, Kanazawa Y, Yoshida H. Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor. Cancer Sci 2019;110:3708-17. [PMID: 31648389 DOI: 10.1111/cas.14221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Schippers AC, Collettini F, Steffen IG, Wieners G, Denecke T, Pavel M, Wust P, Gebauer B. Initial Experience with CT–Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases. Journal of Vascular and Interventional Radiology 2017;28:672-82. [DOI: 10.1016/j.jvir.2016.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Porter MG, Stoeger SM. Atypical Colorectal Neoplasms. Surgical Clinics of North America 2017;97:641-56. [DOI: 10.1016/j.suc.2017.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
81 Zhai H, Li D, Feng Q, Qian X, Li L, Yao J. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database. Int J Surg 2019;66:103-9. [PMID: 30872175 DOI: 10.1016/j.ijsu.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
82 Croome KP, Burns JM, G Que F, Nagorney DM. Hepatic Resection for Metastatic Neuroendocrine Cancer in Patients with Bone Metastases. Ann Surg Oncol 2016;23:3693-8. [PMID: 27188296 DOI: 10.1245/s10434-016-5274-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
83 da Silva TN, van Velthuysen MLF, van Eijck CHJ, Teunissen JJ, Hofland J, de Herder WW. Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep 2018;2018:18-0015. [PMID: 29675259 DOI: 10.1530/EDM-18-0015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
84 Függer R, Gangl O, Fröschl U. Clinical approach to the patient with a solid pancreatic mass. Wien Med Wochenschr 2014;164:73-9. [PMID: 24577681 DOI: 10.1007/s10354-014-0266-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Dillon JS. Workup of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:165-83. [PMID: 32151354 DOI: 10.1016/j.soc.2019.10.002] [Reference Citation Analysis]
86 Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'connor JM, Salazar R, Taal BG, Vullierme MP, O'toole D. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors. Neuroendocrinology 2012;95:120-34. [DOI: 10.1159/000335587] [Cited by in Crossref: 326] [Cited by in F6Publishing: 255] [Article Influence: 36.2] [Reference Citation Analysis]
87 Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol 2016;51:513-23. [PMID: 26605828 DOI: 10.3109/00365521.2015.1115117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
88 Cloyd JM, Wiseman JT, Pawlik TM. Surgical management of pancreatic neuroendocrine liver metastases. J Gastrointest Oncol 2020;11:590-600. [PMID: 32655938 DOI: 10.21037/jgo.2019.11.02] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD;  ENETS consensus conference participants. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol. 2015;26:1604-1620. [PMID: 25646366 DOI: 10.1093/annonc/mdv041] [Cited by in Crossref: 281] [Cited by in F6Publishing: 258] [Article Influence: 46.8] [Reference Citation Analysis]
90 Norton JA, Krampitz G, Jensen RT. Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am 2015;24:795-832. [PMID: 26363542 DOI: 10.1016/j.soc.2015.06.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
91 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
92 Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, Taieb D, Pattou F, Goudet P, Vezzosi D, Scoazec JY, Cadiot G, Borson-Chazot F, Do Cao C; pour la Société française d’endocrinologie et le Groupe d’étude des tumeurs endocrines. [Malignant insulinoma: recommendations for workup and treatment]. Presse Med 2014;43:645-59. [PMID: 24857257 DOI: 10.1016/j.lpm.2013.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
93 Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015;5:119-76. [PMID: 26854147 DOI: 10.3390/diagnostics5020119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
94 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Hoppmann A, Williams AP, Coleman A, Tynes C, Williams GR, Mroczek-Musulman E, Aye J, Whelan KF, Clay MR, Ranganathan S, Beierle EA. Partial response to carboplatin, etoposide phosphate, and atezolizumab in a pediatric patient with high-grade metastatic tumor with rhabdoid and focal neuroendocrine features. Pediatr Blood Cancer 2020;67:e28048. [PMID: 31724272 DOI: 10.1002/pbc.28048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153-171. [PMID: 26742109 DOI: 10.1159/000443171] [Cited by in Crossref: 531] [Cited by in F6Publishing: 453] [Article Influence: 106.2] [Reference Citation Analysis]
97 Sahu S, Schernthaner R, Ardon R, Chapiro J, Zhao Y, Sohn JH, Fleckenstein F, Lin M, Geschwind JF, Duran R. Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization: Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology. 2017;283:883-894. [PMID: 27831830 DOI: 10.1148/radiol.2016160838] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
98 Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: Recent advances and controversies. Curr Opin Gastroenterol. 2013;29:650-661. [PMID: 24100728 DOI: 10.1097/mog.0b013e328365efb1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 21] [Article Influence: 6.6] [Reference Citation Analysis]
99 Tran CG, Sherman SK, Howe JR. The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2021;28:2741-51. [PMID: 33452604 DOI: 10.1245/s10434-020-09566-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol 2013;40:84-99. [PMID: 23391116 DOI: 10.1053/j.seminoncol.2012.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
101 Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, Xu Y, Chi T, Zhao H, Wang W, Cui Q, Zhong S, Huang J, Mao Y. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. Medicine (Baltimore) 2015;94:e388. [PMID: 25590842 DOI: 10.1097/MD.0000000000000388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
102 Garcia-Torralba E, Spada F, Lim KHJ, Jacobs T, Barriuso J, Mansoor W, McNamara MG, Hubner RA, Manoharan P, Fazio N, Valle JW, Lamarca A. Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;94:102168. [PMID: 33730627 DOI: 10.1016/j.ctrv.2021.102168] [Reference Citation Analysis]
103 Han X, Chen W, Chen P, Zhou W, Rong Y, Lv Y, Li JA, Ji Y, Chen W, Lou W, Xu X. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:514-23. [PMID: 32282764 DOI: 10.1097/MPA.0000000000001535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
104 Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS. Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. J Nucl Med. 2017;58:1054-1057. [PMID: 28153957 DOI: 10.2967/jnumed.116.180984] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
105 Ono K, Shiozawa E, Ohike N, Fujii T, Shibata H, Kitajima T, Fujimasa K, Okamoto N, Kawaguchi Y, Nagumo T, Tazawa S, Homma M, Yamochi-Onizuka T, Norose T, Yoshida H, Murakami M, Tate G, Takimoto M. Immunohistochemical CD73 expression status in gastrointestinal neuroendocrine neoplasms: A retrospective study of 136 patients. Oncol Lett 2018;15:2123-30. [PMID: 29434915 DOI: 10.3892/ol.2017.7569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
106 Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Reference Citation Analysis]
107 Yalchin M, Oliveira A, Theocharidou E, Pencharz D, Navalkissoor S, Quigley A, Walker M, Caplin M, Toumpanakis C. The Impact of Radiological Response to Peptide Receptor Radionuclide Therapy on Overall Survival in Patients With Metastatic Midgut Neuroendocrine Tumors. Clinical Nuclear Medicine 2017;42:e135-41. [DOI: 10.1097/rlu.0000000000001457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
108 Dilz LM, Denecke T, Steffen IG, Prasad V, von Weikersthal LF, Pape UF, Wiedenmann B, Pavel M. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015;51:1253-1262. [PMID: 25935542 DOI: 10.1016/j.ejca.2015.04.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
109 Zappa M, Abdel-Rehim M, Hentic O, Vullierme MP, Ruszniewski P, Vilgrain V. Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract. Target Oncol 2012;7:107-16. [PMID: 22707276 DOI: 10.1007/s11523-012-0219-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
110 Sahara K, Merath K, Tsilimigras DI, Hyer JM, Guglielmi A, Aldrighetti L, Weiss M, Fields RC, Poultsides GA, Maithel SK, Endo I, Pawlik TM, other members of the U.s. Neuroendo. Conditional disease‐free survival after curative‐intent liver resection for neuroendocrine liver metastasis. J Surg Oncol 2019;120:1087-95. [DOI: 10.1002/jso.25713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
111 Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR. Predictive Value of 99m Tc-MAA SPECT for 90 Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. J Nucl Med 2015;56:1654-60. [DOI: 10.2967/jnumed.115.162685] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
112 Vialon M, Desailloud R, Caron P. La néoplasie endocrinienne multiple de type 1 : mise au point après le congrès de l’ENETS 2019: Multiple Endocrine Neoplasia Type 1: Development after the ENETS 2019 Congress. Ann Endocrinol (Paris) 2019;80 Suppl 1:S19-28. [PMID: 31606058 DOI: 10.1016/S0003-4266(19)30113-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Krug S, Boch M, Nimphius W, Gress T, Michl P, Rinke A. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. Pancreatology 2017;17:139-45. [DOI: 10.1016/j.pan.2016.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
114 Swierz MJ, Storman D, Riemsma RP, Wolff R, Mitus JW, Pedziwiatr M, Kleijnen J, Bala MM. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Cochrane Database Syst Rev 2020;3:CD009498. [PMID: 32163181 DOI: 10.1002/14651858.CD009498.pub4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Martínez Manzano Á, Balsalobre Salmerón MD, García López MA, Soto García S, Vázquez Rojas JL. Psoriasiform lesions: Uncommon presentation of glucagonoma. Gastroenterol Hepatol 2018;41:500-2. [PMID: 29074313 DOI: 10.1016/j.gastrohep.2017.08.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075-5086. [PMID: 26366058 DOI: 10.2147/dddt.s84177] [Cited by in Crossref: 105] [Cited by in F6Publishing: 52] [Article Influence: 17.5] [Reference Citation Analysis]
117 Tamburrino D, Spoletini G, Partelli S, Muffatti F, Adamenko O, Crippa S, Falconi M. Surgical management of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2016;30:93-102. [PMID: 26971846 DOI: 10.1016/j.beem.2015.10.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
118 Mulholland N, Chakravartty R, Devlin L, Kalogianni E, Corcoran B, Vivian G. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders. Eur J Nucl Med Mol Imaging 2015;42:2002-12. [PMID: 26142730 DOI: 10.1007/s00259-015-3116-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 18.5] [Reference Citation Analysis]
120 Effraimidis G, Knigge U, Rossing M, Oturai P, Rasmussen ÅK, Feldt-Rasmussen U. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin Cancer Biol 2021:S1044-579X(21)00112-7. [PMID: 33905872 DOI: 10.1016/j.semcancer.2021.04.011] [Reference Citation Analysis]
121 Attili F, Capurso G, Vanella G, Fuccio L, Fave GD, Costamagna G, Larghi A. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Digestive and Liver Disease 2014;46:9-17. [DOI: 10.1016/j.dld.2013.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
122 Armstrong EA, Beal EW, Shah M, Konda B, Abdel-Misih S, Ejaz A, Dillhoff ME, Pawlik TM, Cloyd JM. Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection. Hepatobiliary Surg Nutr 2020;9:1-12. [PMID: 32140474 DOI: 10.21037/hbsn.2019.06.02] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
123 de Mestier L, Deguelte-lardière S, Brixi H, Kianmanesh R, Cadiot G. Tumeurs neuroendocrines digestives. La Revue de Médecine Interne 2016;37:551-60. [DOI: 10.1016/j.revmed.2016.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
124 Hackl C, Schlitt HJ, Kirchner GI, Knoppke B, Loss M. Liver transplantation for malignancy: Current treatment strategies and future perspectives. World J Gastroenterol 2014; 20(18): 5331-5344 [PMID: 24833863 DOI: 10.3748/wjg.v20.i18.5331] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
125 Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Strosberg J, Cadiot G, Riechelmann R. International Practice Patterns and Resource Utilization in the Treatment of Neuroendocrine Tumors. Pancreas 2013;42:339-47. [DOI: 10.1097/mpa.0b013e31826707cc] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
126 Chen JX, Wileyto EP, Soulen MC. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial. Trials 2018;19:390. [PMID: 30016989 DOI: 10.1186/s13063-018-2782-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
127 Wang Y, Luo Q, Li Y, Wang H, Deng S, Wei S, Li X. Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. PLoS One. 2014;9:e103939. [PMID: 25105961 DOI: 10.1371/journal.pone.0103939] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
128 Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R;  Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21. [PMID: 24384494 DOI: 10.1016/s1470-2045(13)70362-0] [Cited by in Crossref: 256] [Cited by in F6Publishing: 108] [Article Influence: 36.6] [Reference Citation Analysis]
129 Díaz Del Arco C, Díaz Pérez JÁ, Ortega Medina L, Sastre Valera J, Fernández Aceñero MJ. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors. Endocr Pathol 2016;27:276-83. [PMID: 27688080 DOI: 10.1007/s12022-016-9455-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
130 Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L, Virgolini IJ. Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis. Rev Esp Med Nucl Imagen Mol 2021:S2253-654X(21)00062-7. [PMID: 34384731 DOI: 10.1016/j.remn.2021.03.004] [Reference Citation Analysis]
131 Sakuma Y, Sata N, Endo K, Yasuda Y, Yokota S, Hosoya Y, Shimizu A, Fujii H, Matsubara D, Fukushima N, Asakawa S, Shimada YK, Lefor CK, Lefor AK. An isolated metachronous metastasis to the adrenal gland from a pancreatic neuroendocrine tumor: A case report. Int J Surg Case Rep 2017;41:169-73. [PMID: 29102861 DOI: 10.1016/j.ijscr.2017.10.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
132 Kaçmaz E, Heidsma CM, Besselink MGH, Dreijerink KMA, Klümpen HJ, Nieveen van Dijkum EJM, Engelsman AF. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E403. [PMID: 30909512 DOI: 10.3390/jcm8030403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
133 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Reference Citation Analysis]
134 Mont Alverne Pierre AM, Veras CM, Esmeraldo TM, Schwermann MP, Studart E Neves MS, Bastos Pinho JE, Canito Brasil IR. Liver Transplantation for Non-hepatocellular Carcinoma Malignancy: A Single-Center Experience. Transplant Proc 2019;51:3355-9. [PMID: 31669072 DOI: 10.1016/j.transproceed.2019.09.001] [Reference Citation Analysis]
135 Böning G, Schäfer M, Grupp U, Kaul D, Kahn J, Pavel M, Maurer M, Denecke T, Hamm B, Streitparth F. Comparison of applied dose and image quality in staging CT of neuroendocrine tumor patients using standard filtered back projection and adaptive statistical iterative reconstruction. European Journal of Radiology 2015;84:1601-7. [DOI: 10.1016/j.ejrad.2015.04.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
136 Zatelli MC, Fanciulli G, Malandrino P, Ramundo V, Faggiano A, Colao A; NIKE Group. Predictive factors of response to mTOR inhibitors in neuroendocrine tumours. Endocr Relat Cancer 2016;23:R173-83. [PMID: 26666705 DOI: 10.1530/ERC-15-0413] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
137 Borre M, Dam GA, Knudsen AW, Grønbaek H. Nutritional status and nutritional risk in patients with neuroendocrine tumors. Scand J Gastroenterol 2018;53:284-92. [PMID: 29373941 DOI: 10.1080/00365521.2018.1430848] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
138 Hibi T, Itano O, Shinoda M, Kitagawa Y. Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today 2017;47:403-15. [PMID: 27130463 DOI: 10.1007/s00595-016-1337-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
139 Chan DT, Luk AO, So WY, Kong AP, Chow FC, Ma RC, Lo AW. Natural history and outcome in Chinese patients with gastroenteropancreatic neuroendocrine tumours: - a 17-year retrospective analysis. BMC Endocr Disord. 2016;16:12. [PMID: 26911576 DOI: 10.1186/s12902-016-0087-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
140 Póvoa S, Azevedo D, Marques C, Barroca H, Costa A. Unknown primary large-cell neuroendocrine tumor. Autops Case Rep 2018;8:e2018025. [PMID: 30533401 DOI: 10.4322/acr.2018.025] [Reference Citation Analysis]
141 Nilsson O. Profiling of ileal carcinoids. Neuroendocrinology 2013;97:7-18. [PMID: 22986706 DOI: 10.1159/000343232] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
142 Czeczok TW, Stashek KM, Maxwell JE, O'Dorisio TM, Howe JR, Hornick JL, Bellizzi AM. Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin. Appl Immunohistochem Mol Morphol 2018;26:94-100. [PMID: 29420353 DOI: 10.1097/PAI.0000000000000563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
144 Xie Q, Liu T, Ding J, Zhou N, Meng X, Zhu H, Li N, Yu J, Yang Z. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 2021;48:3129-40. [PMID: 33630145 DOI: 10.1007/s00259-021-05249-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
145 Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819-31. [PMID: 23582921 DOI: 10.1016/j.bpg.2012.12.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
146 Huang PY, Tsai KL, Liang CM, Tai WC, Rau KM, Wu KL, Huang CC, Chuah SK. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. Kaohsiung J Med Sci 2018;34:650-6. [PMID: 30392572 DOI: 10.1016/j.kjms.2018.05.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
147 Teulé A, Casanovas O. Relevance of angiogenesis in neuroendocrine tumors. Target Oncol. 2012;7:93-98. [PMID: 22592949 DOI: 10.1007/s11523-012-0217-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
148 Dréanic J, Lepère C, El Hajjam M, Gouya H, Rougier P, Coriat R. Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? Ther Adv Med Oncol 2016;8:383-7. [PMID: 27583030 DOI: 10.1177/1758834016656495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
149 Gulpinar B, Peker E, Kul M, Elhan AH, Haliloglu N. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features? Abdom Radiol (NY) 2019;44:2147-55. [PMID: 30863999 DOI: 10.1007/s00261-019-01963-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
150 Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer 2015;22:933-40. [PMID: 26373569 DOI: 10.1530/ERC-15-0314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
151 Girard N. Neuroendocrine tumors of the thymus: the oncologist point of view. J Thorac Dis 2017;9:S1491-500. [PMID: 29201452 DOI: 10.21037/jtd.2017.08.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
152 Beleù A, Drudi A, Giaretta A, De Robertis R, Fedrigo I, Martone E, Simone C, Bovo C, D'Onofrio M. Operator Evaluation of Ultrasound Fusion Imaging Usefulness in the Percutaneous Ablation of Hepatic Malignancies: A Prospective Study. Ultrasound Med Biol 2021:S0301-5629(21)00306-9. [PMID: 34392997 DOI: 10.1016/j.ultrasmedbio.2021.07.008] [Reference Citation Analysis]
153 McDermott S, O'Neill AC, Skehan SJ. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach. Clin Imaging 2013;37:194-200. [PMID: 23465968 DOI: 10.1016/j.clinimag.2012.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
154 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
155 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
156 Grosse C, Noack P, Silye R. Accuracy of grading pancreatic neuroendocrine neoplasms with Ki-67 index in fine-needle aspiration cellblock material. Cytopathology 2019;30:187-93. [PMID: 30303569 DOI: 10.1111/cyt.12643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
157 Galleberg R, Knigge U, Tiensuu Janson E, Vestermark L, Haugvik S, Ladekarl M, Langer S, Grønbæk H, Österlund P, Hjortland G, Assmus J, Tang L, Perren A, Sorbye H. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology 2017;43:1682-9. [DOI: 10.1016/j.ejso.2017.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
158 Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging 2014;41:1492-6. [PMID: 24863431 DOI: 10.1007/s00259-014-2805-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
159 Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014;2:8. [PMID: 25332984 DOI: 10.3978/j.issn.2305-5839.2013.03.01] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
160 Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. Crit Rev Oncol Hematol 2016;100:167-76. [PMID: 26917456 DOI: 10.1016/j.critrevonc.2016.02.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
161 Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 6.2] [Reference Citation Analysis]
162 Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2013;14:307-21. [PMID: 23363383 DOI: 10.1517/14656566.2013.767332] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
163 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Reference Citation Analysis]
164 Kawano S, Miyashima Y, Miyabe Y, Kawai Y, Murata T, Uda M, Inokuchi T, Okada H. A case of small intestinal neuroendocrine carcinoma diagnosed using double-balloon endoscopy with long-term survival. Clin J Gastroenterol. 2018;11:240-244. [PMID: 29450787 DOI: 10.1007/s12328-018-0834-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
165 Chan G, Kocha W, Reid R, Taqi A, Wall W, Quan D. Liver transplantation for symptomatic liver metastases of neuroendocrine tumours. Curr Oncol 2012;19:217-21. [PMID: 22876148 DOI: 10.3747/co.19.950] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
166 Moris D, Tsilimigras DI, Ntanasis-stathopoulos I, Beal EW, Felekouras E, Vernadakis S, Fung JJ, Pawlik TM. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery 2017;162:525-36. [DOI: 10.1016/j.surg.2017.05.006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
167 Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging 2016;43:1585-92. [PMID: 26922350 DOI: 10.1007/s00259-016-3328-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
168 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
169 Ethun CG, Postlewait LM, Baptiste GG, McInnis MR, Cardona K, Russell MC, Kooby DA, Staley CA, Maithel SK. Small bowel neuroendocrine tumors: A critical analysis of diagnostic work-up and operative approach. J Surg Oncol 2016;114:671-6. [PMID: 27511436 DOI: 10.1002/jso.24390] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
170 Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database. J Gastrointest Oncol 2019;10:869-77. [PMID: 31602324 DOI: 10.21037/jgo.2019.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
171 Díaz del Arco C, Esteban López-jamar JM, Ortega Medina L, Díaz Pérez JÁ, Fernández Aceñero MJ. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior: GRADING OF PANCREATIC NEUROENDOCRINE TUMORS IN FNA SAMPLES. Diagn Cytopathol 2017;45:29-35. [DOI: 10.1002/dc.23635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
172 Zhang L, Wan D, Bao L, Chen Q, Xie H, Xu S, Lin S. Neuroendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Medicine (Baltimore) 2018;97:e11487. [PMID: 30024526 DOI: 10.1097/MD.0000000000011487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
173 Genç CG, Jilesen AP, Partelli S, Falconi M, Muffatti F, van Kemenade FJ, van Eeden S, Verheij J, van Dieren S, van Eijck CHJ, Nieveen van Dijkum EJM. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg 2018;267:1148-54. [PMID: 28594340 DOI: 10.1097/SLA.0000000000002123] [Cited by in Crossref: 60] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
174 Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol. 2015;22:164-171. [PMID: 25190113 DOI: 10.1245/s10434-014-3981-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
175 Bösch F, Werner J, Angele MK, Guba MO. [Oligometastases of neuroendocrine tumors-extent of surgery]. Chirurg 2018;89:516-22. [PMID: 29876615 DOI: 10.1007/s00104-018-0644-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Basu S, Ranade R, Thapa P. Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model. Nucl Med Commun 2015;36:766-74. [PMID: 25920048 DOI: 10.1097/MNM.0000000000000321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
177 Kandil E, Saeed A, Buell J. Surgical approaches for liver metastases in carcinoid tumors. Gland Surg 2015;4:442-6. [PMID: 26425458 DOI: 10.3978/j.issn.2227-684X.2015.04.10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Tanno L, Mayo D, Mills S, Takhar A, Cave J, Nolan L, Stedman B, Sundram FX, Abu Hilal M, Connor H, Pearce N, Armstrong T. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology 2018;18:304-12. [PMID: 29433805 DOI: 10.1016/j.pan.2017.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
180 Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol 2018;14:216-27. [PMID: 29449689 DOI: 10.1038/nrendo.2018.3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
181 Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, Ezziddin S. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238-1246. [PMID: 25808630 DOI: 10.1007/s00259-015-3041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Petersenn S, Koch CA. Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord 2017;18:373-8. [DOI: 10.1007/s11154-018-9442-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
183 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
184 Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, Cuthbertson DJ, Dobson R, Grozinsky-Glasberg S, Steeds RP, Dreyfus G, Pellikka PA, Toumpanakis C. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors: An Expert Statement. J Am Coll Cardiol 2017;69:1288-304. [PMID: 28279296 DOI: 10.1016/j.jacc.2016.12.030] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 22.3] [Reference Citation Analysis]
185 Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, De Braud F, Buzzoni R. Update on medical treatment of small intestinal neuroendocrine tumors. Expert Rev Anticancer Ther. 2016;16:969-976. [PMID: 27353232 DOI: 10.1080/14737140.2016.1207534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
186 Tsilimigras DI, Squires MH, Cloyd JM, Pawlik TM. Treatment strategies for neuroendocrine liver metastases: an update. Expert Opinion on Orphan Drugs 2019;7:327-35. [DOI: 10.1080/21678707.2019.1651639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, Camerini T, Milione M, Regalia E, Spreafico C, Gangeri L, Buzzoni R, de Braud FG, De Feo T, Mariani L. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant. 2016;16:2892-2902. [PMID: 27134017 DOI: 10.1111/ajt.13831] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
188 Begum N, Wellner U, Thorns C, Brabant G, Hoffmann M, Bürk CG, Lehnert H, Keck T. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention. World J Surg 2015;39:1443-51. [DOI: 10.1007/s00268-015-2963-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
189 Jiménez-fonseca P, Carmona-bayonas A, Martín-pérez E, Crespo G, Serrano R, Llanos M, Villabona C, García-carbonero R, Aller J, Capdevila J, Grande E; On behalf of the Spanish Neuroendocrine Tumor Group (GETNE). Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors. Cancer Metastasis Rev 2015;34:381-400. [DOI: 10.1007/s10555-015-9573-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
190 Iwaya H, Fukukura Y, Hashimoto S, Tanoue S, Kawahira M, Hinokuchi M, Fujita T, Komaki Y, Arima S, Sasaki F, Kanmura S, Higashi M, Tamada K, Ido A. Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms. Pancreatology 2021;21:779-86. [PMID: 33714670 DOI: 10.1016/j.pan.2021.02.020] [Reference Citation Analysis]
191 Solnes LB, Werner RA, Jones KM, Sadaghiani MS, Bailey CR, Lapa C, Pomper MG, Rowe SP. Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. J Nucl Med 2020;61:311-8. [PMID: 31924727 DOI: 10.2967/jnumed.118.220665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
192 Manguso N, Nissen N, Hendifar A, Harit A, Mirocha J, Friedman M, Lipshutz HG, Amersi F. Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases. J Surg Oncol 2019;120:926-31. [PMID: 31396982 DOI: 10.1002/jso.25657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
193 Errasti Alustiza J, Espín Basany E, Reina Duarte A. Rare tumors of the rectum. Narrative review. Cir Esp 2014;92:579-88. [PMID: 24629769 DOI: 10.1016/j.ciresp.2013.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
194 Svensson J, Hagmarker L, Magnander T, Wängberg B, Bernhardt P. Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Phys 2016;3:15. [PMID: 27491429 DOI: 10.1186/s40658-016-0153-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
195 Kiritani S, Arita J, Matsumura M, Nishioka Y, Kudo H, Ichida A, Ishizawa T, Akamatsu N, Kaneko J, Hasegawa K. Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy. Surgery 2020;167:404-9. [DOI: 10.1016/j.surg.2019.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Ataeinia B, Loberg C, Kravets H, Beheshti M, von Mallek D, Mottaghy FM, Heinzel A. Successful palliative peptide receptor radionuclide therapy for impending compression of vena cava due to unresectable liver metastasis of neuroendocrine tumor. EXCLI J 2019;18:273-6. [PMID: 31338000 DOI: 10.17179/excli2019-1220] [Reference Citation Analysis]
197 Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol 2018;91:20180108. [PMID: 30102557 DOI: 10.1259/bjr.20180108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
198 Pencharz D, Walker M, Yalchin M, Quigley AM, Caplin M, Toumpanakis C, Navalkissoor S. Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nucl Med Commun 2017;38:593-600. [PMID: 28471845 DOI: 10.1097/MNM.0000000000000685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
199 Miller HC, Drymousis P, Flora R, Goldin R, Spalding D, Frilling A. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg. 2014;38:1353-1361. [PMID: 24493070 DOI: 10.1007/s00268-014-2451-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
200 Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa SL, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One 2013;8:e61538. [PMID: 23620762 DOI: 10.1371/journal.pone.0061538] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
201 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterology Research and Practice 2018;2018:1-12. [DOI: 10.1155/2018/9647247] [Reference Citation Analysis]
202 Abbas H, Erridge S, Sodergren MH, Papoulas M, Nawaz A, Menon K, Heaton ND, Prachalias AA, Srinivasan P. Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. International Journal of Surgery 2017;44:152-9. [DOI: 10.1016/j.ijsu.2017.06.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
203 Arigoni S, Ignjatovic S, Sager P, Betschart J, Buerge T, Wachtl J, Tschuor C, Limani P, Puhan MA, Lesurtel M, Raptis DA, Breitenstein S. Diagnosis and prediction of neuroendocrine liver metastases: a protocol of six systematic reviews. JMIR Res Protoc 2013;2:e60. [PMID: 24366180 DOI: 10.2196/resprot.2890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
204 Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S, Sapisochin G. The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases. Can J Gastroenterol Hepatol. 2018;2018:9531925. [PMID: 29623268 DOI: 10.1155/2018/9531925] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
205 Klimstra DS. Pathologic Classification of Neuroendocrine Neoplasms. Hematol Oncol Clin North Am. 2016;30:1-19. [PMID: 26614366 DOI: 10.1016/j.hoc.2015.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
206 Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, Maire F, Hammel P, Ruszniewski P, Fenaux P. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocrine-Related Cancer 2016;23:L17-23. [DOI: 10.1530/erc-15-0543] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 6.6] [Reference Citation Analysis]
207 Öberg K. Universal everolimus for malignant neuroendocrine tumours? Lancet 2016;387:924-6. [PMID: 26703890 DOI: 10.1016/S0140-6736(15)01234-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
208 Challis BG, Powlson AS, Casey RT, Pearson C, Lam BY, Ma M, Pitfield D, Yeo GSH, Godfrey E, Cheow HK, Chatterjee VK, Carroll NR, Shaw A, Buscombe JR, Simpson HL. Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management. Endocr Connect 2017;6:540-8. [PMID: 28784625 DOI: 10.1530/EC-17-0076] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
209 Lin C, Dai H, Hong X, Pang H, Wang X, Xu P, Jiang J, Wu W, Zhao Y. The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases. Pancreatology 2018;18:608-14. [PMID: 29731245 DOI: 10.1016/j.pan.2018.04.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
210 Higashino N, Sonomura T, Ito D, Fukuda K, Ikoma A, Funayama Y, Kuriyama S, Kawamura N, Tanaka R, Kamisako A, Koyama T, Sato H, Kitano M, Kawai N. Usefulness of computed tomography during arteriography in a selective arterial calcium agent injection test for pancreatic gastrinoma: a case description. Quant Imaging Med Surg 2021;11:3898-903. [PMID: 34341759 DOI: 10.21037/qims-20-1224] [Reference Citation Analysis]
211 Lombardi M, De Lio N, Funel N, Sardella C, Russo D, Urbani C, Rossi G, Campani D, Martino E, Marcocci C, Boggi U, Bogazzi F. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET. J Endocrinol Invest 2015;38:605-13. [DOI: 10.1007/s40618-014-0219-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
212 Lind A, Wängberg B, Ellegård L. Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET). Eur J Clin Nutr 2016;70:990-4. [PMID: 27026421 DOI: 10.1038/ejcn.2016.40] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
213 Malik L, Chua YJ, Butt NS, Yip D. Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory. Asia Pac J Clin Oncol. 2016;12:e133-e140. [PMID: 24164683 DOI: 10.1111/ajco.12121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
214 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Reference Citation Analysis]
215 Mohan H, Nicholson P, Winter DC, O'Shea D, O'Toole D, Geoghegan J, Maguire D, Hoti E, Traynor O, Cantwell CP. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol. 2015;26:935-942.e1. [PMID: 25840836 DOI: 10.1016/j.jvir.2014.12.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
216 Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014;171:R111-R122. [PMID: 24891137 DOI: 10.1530/eje-14-0113] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
217 Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 2016;12:313-21. [PMID: 26759064 DOI: 10.2217/fon.15.321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
218 Kennedy A. Liver metastases from neuroendocrine tumors. Future Oncology 2014;10:83-7. [DOI: 10.2217/fon.14.231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
219 Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J. Comparison of the Impact of 68 Ga-DOTATATE and 18 F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. J Nucl Med 2017;58:91-6. [DOI: 10.2967/jnumed.116.178095] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 13.6] [Reference Citation Analysis]
220 La Rosa S, Casnedi S, Maragliano R, Goyault G, Weber JC, Louis B, Schlund E, Sessa F. Breast metastasis as the first clinical manifestation of ileal neuroendocrine tumor. A challenging diagnosis with relevant clinical implications. Endocr Pathol 2015;26:145-51. [PMID: 25935445 DOI: 10.1007/s12022-015-9371-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
221 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
222 Couvelard A, Pélaprat D, Dokmak S, Sauvanet A, Voisin T, Couvineau A, Ruszniewski P. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors. Pancreas 2017;46:631-8. [DOI: 10.1097/mpa.0000000000000813] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
223 Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer H, Simon B, Höller T, Biersack H, Nagarajah J. Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18 F-FDG PET: Feasibility of a Metabolic Grading System. J Nucl Med 2014;55:1260-6. [DOI: 10.2967/jnumed.114.137166] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
224 Delker A, Ilhan H, Zach C, Brosch J, Gildehaus FJ, Lehner S, Bartenstein P, Böning G. The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors. Mol Imaging Biol 2015;17:726-34. [PMID: 25790773 DOI: 10.1007/s11307-015-0839-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
225 Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
226 Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017;9:189-199. [PMID: 28344664 DOI: 10.1177/1758834016678149] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
227 Kos-Kudła B. Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemp Oncol (Pozn) 2015;19:345-9. [PMID: 26793016 DOI: 10.5114/wo.2015.56006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
228 Prasad V, Steffen IG, Pavel M, Denecke T, Tischer E, Apostolopoulou K, Pascher A, Arsenic R, Brenner W. Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids. EJNMMI Res 2015;5:53. [PMID: 26458908 DOI: 10.1186/s13550-015-0130-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
229 Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS. Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. EJNMMI Res 2014;4:38. [PMID: 26116109 DOI: 10.1186/s13550-014-0038-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
230 Niederle B, Selberherr A, Niederle MB. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? Curr Oncol Rep 2021;23:85. [PMID: 34018081 DOI: 10.1007/s11912-021-01074-2] [Reference Citation Analysis]
231 Mittra ES. Neuroendocrine Tumor Therapy: 177Lu-DOTATATE. AJR Am J Roentgenol 2018;211:278-85. [PMID: 29949416 DOI: 10.2214/AJR.18.19953] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 8.7] [Reference Citation Analysis]
232 de Hosson LD, Takkenkamp TJ, Kats-Ugurlu G, Bouma G, Bulthuis M, de Vries EGE, van Faassen M, Kema IP, Walenkamp AME. Neuroendocrine tumours and their microenvironment. Cancer Immunol Immunother 2020;69:1449-59. [PMID: 32270230 DOI: 10.1007/s00262-020-02556-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol 2015;3:895-905. [PMID: 26165399 DOI: 10.1016/S2213-8587(15)00043-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
234 Pavel M, Unger N, Borbath I, Ricci S, Hwang TL, Brechenmacher T, Park J, Herbst F, Beaumont JL, Bechter O. Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. Target Oncol. 2016;11:667-675. [PMID: 27193465 DOI: 10.1007/s11523-016-0440-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
235 Pericleous M, Toumpanakis C, Lumgair H, Caplin ME, Morgan-Rowe L, Clark I, Luong TV. Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Case Rep Oncol. 2012;5:313-319. [PMID: 22740822 DOI: 10.1159/000339611] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
236 Wang W, Seeruttun SR, Fang C, Zhou Z. Comprehensive treatment of a functional pancreatic neuroendocrine tumor with multifocal liver metastases. Chin J Cancer Res. 2014;26:501-506. [PMID: 25232226 DOI: 10.3978/j.issn.1000-9604.2014.08.16] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V. Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible? Endocr Connect 2017;6:33-8. [PMID: 28069898 DOI: 10.1530/EC-16-0092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
238 Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol 2015;45:1131-8. [PMID: 26378090 DOI: 10.1093/jjco/hyv143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
239 Luo Y, Ameli S, Pandey A, Khoshpouri P, Ghasabeh MA, Pandey P, Li Z, Hu D, Kamel IR. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019;29:5804-5812. [PMID: 31073860 DOI: 10.1007/s00330-019-06246-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
240 Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus F, Bartenstein P, Angele MK, Haug AR. Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum. Ann Surg Oncol 2015;22:164-71. [DOI: 10.1245/s10434-014-3981-2] [Reference Citation Analysis]
241 Bösch F, Altendorf-Hofmann A, Jacob S, Auernhammer CJ, Spitzweg C, Boeck S, Schubert-Fritschle G, Werner J, Kirchner T, Angele MK, Knösel T. Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. J Clin Med 2020;9:E3368. [PMID: 33096620 DOI: 10.3390/jcm9103368] [Reference Citation Analysis]
242 Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer 2016;16:858. [PMID: 27821081 DOI: 10.1186/s12885-016-2901-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
243 Khan MS, Caplin ME. The use of biomarkers in neuroendocrine tumours. Frontline Gastroenterol 2013;4:175-81. [PMID: 28839724 DOI: 10.1136/flgastro-2012-100272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
244 Ierardi AM, Biondetti P, Padovano B, Magenta Biasina A, Bongini M, Carrafiello G. Intra-caval Percutaneous Radiofrequency Ablation for a Neuroendocrine Tumor (NET) Metastasis in Transplanted Liver. Cardiovasc Intervent Radiol 2018;41:1962-7. [PMID: 30014252 DOI: 10.1007/s00270-018-2032-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): Guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17:29-37. [PMID: 25186181 DOI: 10.1111/hpb.12326] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 13.9] [Reference Citation Analysis]
246 Asban A, Patel AJ, Reddy S, Wang T, Balentine CJ, Chen H. Cancer of the Endocrine System. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1074-1107.e11. [DOI: 10.1016/b978-0-323-47674-4.00068-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin 2014;24:333-49. [PMID: 25065935 DOI: 10.1016/j.thorsurg.2014.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
248 Orgera G, Krokidis M, Cappucci M, Gourtsoyianni S, Tipaldi MA, Hatzidakis A, Rebonato A, Rossi M. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs). Cardiovasc Intervent Radiol. 2015;38:13-24. [PMID: 25366087 DOI: 10.1007/s00270-014-1005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
249 Milin S, Brunaud L, Orry X, Bastien C, Klein M, Bresler L, Laurent V. Prevalence of hepatic lesion types defined by T2-weighted and dynamic gadolinium-enhanced MR imaging in patients with metastasized neuroendocrine tumors. Abdom Radiol (NY) 2016;41:2132-41. [PMID: 27315078 DOI: 10.1007/s00261-016-0814-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
250 Chougnet CN, Leboulleux S, Caramella C, Lumbroso J, Borget I, Déandreis D, Duvillard P, Elias D, de Baere T, Vélayoudom-céphise F, Guigay J, Ducreux M, Schlumberger M, Baudin E. Frequency and characterization of gastro–entero–pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocrine-Related Cancer 2013;20:229-39. [DOI: 10.1530/erc-12-0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
251 Sadowski SM, Cadiot G, Dansin E, Goudet P, Triponez F. The future: surgical advances in MEN1 therapeutic approaches and management strategies. Endocr Relat Cancer 2017;24:T243-60. [PMID: 28811298 DOI: 10.1530/ERC-17-0285] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
252 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015;121:1172-86. [PMID: 25274401 DOI: 10.1002/cncr.28760] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 11.9] [Reference Citation Analysis]
253 Shaheen S, Moradi F, Gamino G, Kunz PL. Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. Curr Treat Options Oncol 2020;21:25. [PMID: 32172368 DOI: 10.1007/s11864-020-0711-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
254 Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, Muto M, Gasperi M, Del Prete F, Colao A, Montesarchio V, Faggiano A; ENETS Centre of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest 2017;40:1373-80. [DOI: 10.1007/s40618-017-0723-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
255 Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival? Orphanet J Rare Dis 2021;16:30. [PMID: 33446229 DOI: 10.1186/s13023-021-01677-9] [Reference Citation Analysis]
256 Costa F, Gumz B. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours. Eur Endocrinol 2014;10:70-4. [PMID: 29872467 DOI: 10.17925/EE.2014.10.01.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
257 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
258 Cui Y, Li ZW, Li XT, Gao SY, Li Y, Li J, Zhu HC, Tang L, Cao K, Sun YS. Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma. Oncotarget 2017;8:108146-55. [PMID: 29296230 DOI: 10.18632/oncotarget.22554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
259 Nadler A, Cukier M, Rowsell C, Kamali S, Feinberg Y, Singh S, Law CH. Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Arch 2013;462:501-5. [PMID: 23588555 DOI: 10.1007/s00428-013-1410-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
260 Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015;10:e0143822. [PMID: 26630134 DOI: 10.1371/journal.pone.0143822] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
261 Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, Biersack H, Ahmadzadehfar H. 90 Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy. J Nucl Med 2012;53:1663-9. [DOI: 10.2967/jnumed.112.107482] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
262 Anlauf M, Neumann M, Bomberg S, Luczak K, Heikaus S, Gustmann C, Antke C, Ezziddin S, Fottner C, Pavel M, Pape UF, Rinke A, Lahner H, Schott M, Cremer B, Hörsch D, Baum RP, Groh U, Alkatout I, Rudlowski C, Scheler P, Zirbes TK, Hoffmann J, Fehm T, Gabbert HE, Baldus SE. [Neuroendocrine neoplasms of the breast]. Pathologe 2015;36:261-70. [PMID: 25986886 DOI: 10.1007/s00292-015-0024-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
263 Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z, Krausch M, Möhlendick B, Topp SA, Piekorz RP, Huckenbeck W, Stoecklein NH, Anlauf M, Knoefel WT. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines. PLoS One 2014;9:e88713. [PMID: 24551139 DOI: 10.1371/journal.pone.0088713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
264 Lv Y, Pu N, Mao W, Chen W, Wang H, Han X, Ji Y, Zhang L, Jin D, Lou W, Xu X. Development of predictive prognostic nomogram for NECs of rectum on population-based exploration. Endocr Connect 2018:/journals/ec/aop/ec-18-0353. [PMID: 30352397 DOI: 10.1530/EC-18-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
265 Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas 2015;44:181-9. [PMID: 25479584 DOI: 10.1097/MPA.0000000000000262] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
266 Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Nakajima TE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 2021;28:1-25. [PMID: 33200538 DOI: 10.1002/jhbp.868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
267 Circelli L, Sciammarella C, Guadagno E, Tafuto S, del Basso de Caro M, Botti G, Pezzullo L, Aria M, Ramundo V, Tatangelo F, Losito NS, Ieranò C, D'Alterio C, Izzo F, Ciliberto G, Colao A, Faggiano A, Scala S. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR. Oncotarget 2016;7:18865-75. [PMID: 26934559 DOI: 10.18632/oncotarget.7738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
268 Rossi RE, Massironi S, Spampatti MP, Conte D, Ciafardini C, Cavalcoli F, Peracchi M. Treatment of liver metastases in patients with digestive neuroendocrine tumors. J Gastrointest Surg. 2012;16:1981-1992. [PMID: 22829240 DOI: 10.1007/s11605-012-1951-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
269 Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26:737-753. [PMID: 23582916 DOI: 10.1016/j.bpg.2012.12.003] [Cited by in Crossref: 119] [Cited by in F6Publishing: 95] [Article Influence: 14.9] [Reference Citation Analysis]
270 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
271 Doherty G. Surgical treatment of neuroendocrine tumors (including carcinoid): . Current Opinion in Endocrinology & Diabetes and Obesity 2013;20:32-6. [DOI: 10.1097/med.0b013e32835b7efa] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
272 Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology 2015;11:1947-59. [DOI: 10.2217/fon.15.86] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
273 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018;2018:9647247. [PMID: 30140282 DOI: 10.1155/2018/9647247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
274 Vinik AI, Chaya C. Clinical Presentation and Diagnosis of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:21-48. [PMID: 26614367 DOI: 10.1016/j.hoc.2015.08.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
275 Hart EA, Meijs TA, Meijer RCA, Dreijerink KM, Tesselaar ME, de Groot CA, Valk GD, Chamuleau SAJ. Carcinoid heart disease: a guide for screening and timing of surgical intervention. Neth Heart J 2017;25:471-8. [PMID: 28631210 DOI: 10.1007/s12471-017-1011-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
276 Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 2014;10:2259-77. [PMID: 25471038 DOI: 10.2217/fon.14.139] [Cited by in Crossref: 95] [Cited by in F6Publishing: 77] [Article Influence: 15.8] [Reference Citation Analysis]
277 Del Prete M, Fiore F, Modica R, Marotta V, Marciello F, Ramundo V, Di Sarno A, Carratù A, di Roseto Cde L, Tafuto S, Tatangelo F, Baldelli R, Colao A, Faggiano A; Multidisciplinary Group for NeuroEndocrine Tumors of Naples. Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res 2014;33:43. [PMID: 24887262 DOI: 10.1186/1756-9966-33-43] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
278 Baudin E, Planchard D, Scoazec JY, Guigay J, Dromain C, Hadoux J, Debaere T, Elias D, Ducreux M. Intervention in gastro-enteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:855-865. [PMID: 23582924 DOI: 10.1016/j.bpg.2013.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
279 Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer. 2015;22:289-298. [PMID: 25770151 DOI: 10.1530/erc-15-0075] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
280 Phan AT, Dave B. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors. Cancer Med 2016;5:2953-64. [PMID: 27539383 DOI: 10.1002/cam4.742] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
281 Xu TM, Wang CS, Jia CW, Qian JM, Li JN. Clinicopathological features of primary gastric neuroendocrine neoplasms: A single-center analysis: Clinicopathological features of GNENs. Journal of Digestive Diseases 2016;17:162-8. [DOI: 10.1111/1751-2980.12326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
282 Varkey J, Simrén M, Jalanko H, Oltean M, Saalman R, Gudjonsdottir A, Gäbel M, Borg H, Edenholm M, Bentdal O, Husby S, Staun M, Mäkisalo H, Bosaeus I, Olausson M, Pakarinen M, Herlenius G. Fifteen years' experience of intestinal and multivisceral transplantation in the Nordic countries. Scand J Gastroenterol 2015;50:278-90. [PMID: 25592555 DOI: 10.3109/00365521.2014.999255] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
283 Kim BS, Park YS, Yook JH, Oh ST, Kim BS. Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme. Medicine (Baltimore). 2015;94:e1748. [PMID: 26554772 DOI: 10.1097/md.0000000000001748] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
284 Kruljac I, Vurnek I, Maasberg S, Kust D, Blaslov K, Ladika Davidović B, Štefanović M, Demirović A, Bišćanin A, Filipović-čugura J, Marić Brozić J, Pape U, Vrkljan M. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms. Endocrine 2018;60:395-406. [DOI: 10.1007/s12020-018-1592-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
285 Fabian E, Haas B, Kump P, Lipp R, Kornprat P, Lutfi A, Talakic E, Fuchsjäger M, Spindelboeck W, Lackner C, Zollner G, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr 2016;128:277-86. [PMID: 26919853 DOI: 10.1007/s00508-016-0965-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
286 Chung H, Chapman WC. Liver transplantation for metastatic neuroendocrine tumors. Adv Surg. 2014;48:235-252. [PMID: 25293619 DOI: 10.1016/j.yasu.2014.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
287 Ikeda M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Kondo S, Morizane C, Ueno H, Okusaka T. Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. J Hepatobiliary Pancreat Sci 2015;22:623-7. [PMID: 25755102 DOI: 10.1002/jhbp.228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
288 Rodrigues Â, Castro-Poças F, Pedroto I. Neuroendocrine Rectal Tumors: Main Features and Management. GE Port J Gastroenterol 2015;22:213-20. [PMID: 28868410 DOI: 10.1016/j.jpge.2015.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
289 Tsang ES, Loree JM, Davies JM, Gill S, Liu D, Ho S, Renouf DJ, Lim HJ, Kennecke HF. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Can J Gastroenterol Hepatol 2020;2020:5104082. [PMID: 33299824 DOI: 10.1155/2020/5104082] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
290 Shin Y, Ha SY, Hyeon J, Lee B, Lee J, Jang KT, Kim KM, Park YS, Park CK. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Res Treat. 2015;47:738-746. [PMID: 25687852 DOI: 10.4143/crt.2014.224] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
291 Birnbaum DJ, Turrini O, Ewald J, Barbier L, Autret A, Hardwigsen J, Brunet C, Moutardier V, Le Treut YP, Delpero JR. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival. Eur J Surg Oncol. 2014;40:1564-1571. [PMID: 25086992 DOI: 10.1016/j.ejso.2014.06.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
292 Spolverato G, Bagante F, Tsilimigras DI, Pawlik TM. Liver transplantation in patients with liver metastases from neuroendocrine tumors. Minerva Chir 2019;74:399-406. [PMID: 31280548 DOI: 10.23736/S0026-4733.19.08119-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
293 Pollard J, McNeely P, Menda Y. Nuclear Imaging of Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020;29:209-221. [PMID: 32151356 DOI: 10.1016/j.soc.2019.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
294 Cui Y, Li X, Gao S, Li Z, Li Y, Lu M, Sun Y. Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms. Chin J Cancer Res 2018;30:31-9. [PMID: 29545717 DOI: 10.21147/j.issn.1000-9604.2018.01.04] [Reference Citation Analysis]
295 Holzer K. Gastroenteropankreatische neuroendokrine Tumoren: Zielgerichtete Diagnostik und Therapie. Chirurg 2014;85:731-44. [DOI: 10.1007/s00104-013-2679-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
296 Gallo M, Malandrino P, Fanciulli G, Rota F, Faggiano A, Colao A; On behalf of NIKE Group. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol 2017;143:1209-24. [DOI: 10.1007/s00432-017-2407-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
297 Kamilaris CDC, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.Front Endocrinol (Lausanne). 2019;10:339. [PMID: 31263451 DOI: 10.3389/fendo.2019.00339] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
298 O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719-735. [PMID: 23582915 DOI: 10.1016/j.bpg.2013.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 5.5] [Reference Citation Analysis]
299 Han X, Zhang C, Tang M, Xu X, Liu L, Ji Y, Pan B, Lou W. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. European Journal of Gastroenterology & Hepatology 2015;27:527-35. [DOI: 10.1097/meg.0000000000000332] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]
300 Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget 2016;7:5538-47. [PMID: 26701729 DOI: 10.18632/oncotarget.6686] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
301 Braat AJ, Smits ML, Braat MN, van den Hoven AF, Prince JF, de Jong HW, van den Bosch MA, Lam MG. ⁹⁰Y Hepatic Radioembolization: An Update on Current Practice and Recent Developments. J Nucl Med 2015;56:1079-87. [PMID: 25952741 DOI: 10.2967/jnumed.115.157446] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
302 Hain E, Sindayigaya R, Fawaz J, Gharios J, Bouteloup G, Soyer P, Bertherat J, Prat F, Terris B, Coriat R, Gaujoux S. Surgical management of pancreatic neuroendocrine tumors: an introduction. Expert Rev Anticancer Ther 2019;19:1089-100. [PMID: 31825691 DOI: 10.1080/14737140.2019.1703677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
303 Yalcin S, Bayram F, Erdamar S, Kucuk O, Oruc N, Coker A. Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci 2017;13:271-82. [PMID: 28261279 DOI: 10.5114/aoms.2017.65449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
304 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Reference Citation Analysis]
305 Sommer WH, Ceelen F, García-albéniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol 2013;23:3094-103. [DOI: 10.1007/s00330-013-2925-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
306 Hijioka S, Sakuma K, Aoki M, Mizuno N, Kuwahara T, Okuno N, Hara K, Yatabe Y. Clinical and in vitro studies of the correlation between MGMT and the effect of streptozocin in pancreatic NET. Cancer Chemother Pharmacol 2019;83:43-52. [PMID: 30310970 DOI: 10.1007/s00280-018-3700-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
307 Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017;8:1079-99. [PMID: 29299370 DOI: 10.21037/jgo.2017.09.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
308 Dumlu EG, Karakoç D, Özdemir A. Nonfunctional Pancreatic Neuroendocrine Tumors: Advances in Diagnosis, Management, and Controversies. Int Surg 2015;100:1089-97. [PMID: 25590518 DOI: 10.9738/INTSURG-D-14-00204.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
309 Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D. A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. J Cancer Res Clin Oncol 2015;141:1639-44. [PMID: 25773126 DOI: 10.1007/s00432-015-1954-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
310 Fehrenbach U, Xin S, Hartenstein A, Auer TA, Dräger F, Froböse K, Jann H, Mogl M, Amthauer H, Geisel D, Denecke T, Wiedenmann B, Penzkofer T. Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making. Cancers (Basel) 2021;13:2726. [PMID: 34072865 DOI: 10.3390/cancers13112726] [Reference Citation Analysis]
311 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017;46:715-731. [PMID: 28609357 DOI: 10.1097/mpa.0000000000000846] [Cited by in Crossref: 127] [Cited by in F6Publishing: 57] [Article Influence: 42.3] [Reference Citation Analysis]
312 Signore A, Lauri C, Auletta S, Varani M, Onofrio L, Glaudemans AWJM, Panzuto F, Marchetti P. Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. Cancers (Basel) 2020;12:E781. [PMID: 32218303 DOI: 10.3390/cancers12040781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
313 Sposito C, Droz Dit Busset M, Citterio D, Bongini M, Mazzaferro V. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. Rev Endocr Metab Disord 2017;18:473-83. [PMID: 29359266 DOI: 10.1007/s11154-017-9439-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
314 Xue M, Shafie A, Qaiser T, Rajpoot NM, Kaltsas G, James S, Gopalakrishnan K, Fisk A, Dimitriadis GK, Grammatopoulos DK, Rabbani N, Thornalley PJ, Weickert MO. Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET). Oncotarget 2017;8:76961-73. [PMID: 29100361 DOI: 10.18632/oncotarget.20290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Souche R, Coignac A, Dupuy M, Bertrand M, Raingeart I, Guiu B, Herrero A, Panaro F, Obled S, Portales F, Riviere B, Ramos J, Borie F, Quenet F, Colombo PE, Prudhomme M, Assenat E, Fabre JM; Renaten Languedoc-Roussillon Study Group., Réseau de référence clinique pour les tumeurs endocrines malignes sporadiques et héréditaires. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol 2020;44:286-94. [PMID: 31543336 DOI: 10.1016/j.clinre.2019.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Merino-Casabiel X, Aller J, Arbizu J, García-Figueiras R, González C, Grande E, Jiménez-Fonseca P, Sevilla MI, Capdevila J. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol 2018;20:1522-8. [PMID: 29766455 DOI: 10.1007/s12094-018-1881-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
317 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today 2014;19:458-68. [DOI: 10.1016/j.drudis.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
318 Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178-189. [PMID: 24982766 DOI: 10.3978/j.issn.2078-6891.2014.037] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
319 Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. GIPR expression in gastric and duodenal neuroendocrine tumors. J Surg Res 2014;190:587-93. [PMID: 24565507 DOI: 10.1016/j.jss.2014.01.044] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
320 Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, Zannino D, Hicks RJ. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015;42:176-85. [PMID: 25209134 DOI: 10.1007/s00259-014-2906-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 7.9] [Reference Citation Analysis]
321 Schwarz C, Kaczirek K, Bodingbauer M. Liver resection for non-colorectal metastases. Eur Surg 2018;50:113-6. [PMID: 29875799 DOI: 10.1007/s10353-018-0528-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
322 Watzka FM, Fottner C, Miederer M, Schad A, Weber MM, Otto G, Lang H, Musholt TJ. Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg. 2015;400:349-358. [PMID: 25682055 DOI: 10.1007/s00423-015-1277-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
323 Spolverato G, Vitale A, Ejaz A, Kim Y, Cosgrove D, Schlacter T, Geschwind J, Pawlik TM. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery 2015;158:339-48. [DOI: 10.1016/j.surg.2015.03.033] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
324 Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Endocrine. 2018;60:15-27. [PMID: 29019150 DOI: 10.1007/s12020-017-1420-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
325 Lavelle L, O'neill A, Mcmahon C, Cantwell C, Heffernan E, Malone D, Daly L, Skehan S. Is diffusion-weighted MRI sufficient for follow-up of neuroendocrine tumour liver metastases? Clinical Radiology 2016;71:863-8. [DOI: 10.1016/j.crad.2016.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
326 Kang XN, Zhang XY, Bai J, Wang ZY, Yin WJ, Li L. Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm. World J Gastrointest Oncol 2019; 11(5): 436-448 [PMID: 31139313 DOI: 10.4251/wjgo.v11.i5.436] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
327 Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74-87. [PMID: 22262004 DOI: 10.1159/000335595] [Cited by in Crossref: 171] [Cited by in F6Publishing: 144] [Article Influence: 19.0] [Reference Citation Analysis]
328 Stump R, Haueis S, Kalt N, Tschuor C, Limani P, Raptis DA, Puhan MA, Breitenstein S. Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews. JMIR Res Protoc. 2013;2:e58. [PMID: 24366112 DOI: 10.2196/resprot.2891] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
329 Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017;6:44-8. [PMID: 28123727 DOI: 10.3892/mco.2016.1097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
330 Rogowski P, von Bestenbostel R, Walter F, Straub K, Nierer L, Kurz C, Landry G, Reiner M, Auernhammer CJ, Belka C, Niyazi M, Corradini S. Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors. Cancers (Basel) 2021;13:1523. [PMID: 33810244 DOI: 10.3390/cancers13071523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
331 Kamieniarz L, Armeni E, O’mahony LF, Leigh C, Miah L, Narayan A, Bhatt A, Cox N, Mandair D, Navalkissoor S, Caplin M, Toumpanakis C. Orbital metastases from neuroendocrine neoplasms: clinical implications and outcomes. Endocrine 2020;67:485-93. [DOI: 10.1007/s12020-019-02130-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
332 Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiol 2016;57:260-70. [DOI: 10.1177/0284185115579932] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
333 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
334 Tsunenari T, Aosasa S, Ogata S, Hoshikawa M, Nishikawa M, Noro T, Shinto E, Tsujimoto H, Ueno H, Hamabe F, Shinmoto H, Hase K, Yamamoto J. Synchronous neuroendocrine tumors in both the pancreas and ileum: A case report. Int J Surg Case Rep 2016;22:47-50. [PMID: 27046104 DOI: 10.1016/j.ijscr.2016.03.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
335 Mandair D, Caplin ME. Colonic and rectal NET's. Best Pract Res Clin Gastroenterol 2012;26:775-89. [PMID: 23582918 DOI: 10.1016/j.bpg.2013.01.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
336 Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol 2015;11:853-64. [PMID: 25757686 DOI: 10.2217/fon.14.285] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
337 Tripathy S, Kumar R. Role of Serial 68Ga DOTANOC PET-CT Scans in Follow-up of Metastatic Bronchial Carcinoid: 12 Year Follow-up From a Tertiary Care Institute. Clin Nucl Med 2019;44:602-3. [PMID: 31021915 DOI: 10.1097/RLU.0000000000002593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.Abdom Radiol (NY). 2020;. [PMID: 33095312 DOI: 10.1007/s00261-020-02833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
339 Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. J Surg Oncol 2015;112:125-32. [PMID: 26171686 DOI: 10.1002/jso.23973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
340 Bösch F, Ilhan H, Pfahler V, Thomas M, Knösel T, Eibl V, Pratschke S, Bartenstein P, Seidensticker M, Auernhammer CJ, Spitzweg C, Guba MO, Werner J, Angele MK. Radioembolization for neuroendocrine liver metastases is safe and effective prior to major hepatic resection. Hepatobiliary Surg Nutr 2020;9:312-21. [PMID: 32509817 DOI: 10.21037/hbsn.2019.07.11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
341 Barat M, Cottereau AS, Kedra A, Dermine S, Palmieri LJ, Coriat R, Dautry R, Tselikas L, Soyer P, Dohan A. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020;9:E2302. [PMID: 32698459 DOI: 10.3390/jcm9072302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
342 Deleval N, Pesque L, Dieudonné A, Viry F, Hentic O, Lebtahi R, Ruszniewski P, de Mestier L. Prognostic impact of bone metastases detected by 18F-DOPA PET in patients with metastatic midgut neuroendocrine tumors. Eur Radiol 2021;31:4166-74. [PMID: 33247341 DOI: 10.1007/s00330-020-07554-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
343 Cloutier J, Thompson ED, Cimino-Mathews A, Rooper LM, Matoso A, Argani P. Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs. Hum Pathol 2018;82:76-86. [PMID: 30031098 DOI: 10.1016/j.humpath.2018.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
344 Iglesias P, Lafuente C, Martín Almendra MÁ, López Guzmán A, Castro JC, Díez JJ. Insulinoma: a multicenter, retrospective analysis of three decades of experience (1983-2014). Endocrinol Nutr 2015;62:306-13. [PMID: 26050581 DOI: 10.1016/j.endonu.2015.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
345 El Rassy E, Tabchi S, Kourie HR, Assi T, Chebib R, Farhat F, Kattan J. Pancreatic small cell cancer. Clinics and Research in Hepatology and Gastroenterology 2016;40:276-80. [DOI: 10.1016/j.clinre.2015.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
346 Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors. Endocrine-Related Cancer 2016;23:625-33. [DOI: 10.1530/erc-16-0117] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
347 Cavalcoli F, Garrahy A, Castellaneta M, Tamagno G. Epidemiology of Neuroendocrine Tumours: By Site of Tumour and by Geographical Area. In: Colao A, Faggiano A, de Herder W, editors. Neuroendocrine Tumors in Real Life. Cham: Springer International Publishing; 2018. pp. 3-27. [DOI: 10.1007/978-3-319-59024-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, Sudan DL, Knechtle SJ, Barbas AS. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS One. 2019;14:e0220527. [PMID: 31365594 DOI: 10.1371/journal.pone.0220527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
349 Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH. Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer 2012;19:615-23. [PMID: 22736724 DOI: 10.1530/ERC-11-0382] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
350 Egger ME, Armstrong E, Martin RC 2nd, Scoggins CR, Philips P, Shah M, Konda B, Dillhoff M, Pawlik TM, Cloyd JM. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. J Am Coll Surg. 2020;230:363-370. [PMID: 32032719 DOI: 10.1016/j.jamcollsurg.2019.12.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
351 Sabet A, Biersack H, Ezziddin S. Advances in Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine 2016;46:40-6. [DOI: 10.1053/j.semnuclmed.2015.09.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
352 Basuroy R, Haji A, Ramage JK, Quaglia A, Srirajaskanthan R. Review article: the investigation and management of rectal neuroendocrine tumours. Aliment Pharmacol Ther. 2016;44:332-345. [PMID: 27302838 DOI: 10.1111/apt.13697] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
353 Soulen MC, van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. Pancreas 2018;47:980-4. [DOI: 10.1097/mpa.0000000000001115] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
354 Marques B, Martins RG, Tralhão G, Couto J, Saraiva S, Ferrão H, Ribeiro J, Santos J, Martins T, Cadime AT, Rodrigues F. Gastric neuroendocrine neoplasm with late liver metastasis. Endocrinol Diabetes Metab Case Rep 2018;2018:18-0048. [PMID: 30083348 DOI: 10.1530/EDM-18-0048] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
355 Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere T. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013;20:649-657. [PMID: 23845449 DOI: 10.1530/erc-13-0027] [Cited by in Crossref: 187] [Cited by in F6Publishing: 82] [Article Influence: 23.4] [Reference Citation Analysis]
356 Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med 2019;60:377-85. [PMID: 30115686 DOI: 10.2967/jnumed.118.215848] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 10.7] [Reference Citation Analysis]
357 Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 2019;19:575. [PMID: 31196127 DOI: 10.1186/s12885-019-5794-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
358 Blank A, Wehweck L, Marinoni I, Boos LA, Bergmann F, Schmitt AM, Perren A. Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Arch 2015;467:543-50. [PMID: 26384025 DOI: 10.1007/s00428-015-1843-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
359 Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, Takayanagi R, Shimatsu A. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50:58-64. [PMID: 24499825 DOI: 10.1007/s00535-014-0934-2] [Cited by in Crossref: 179] [Cited by in F6Publishing: 140] [Article Influence: 25.6] [Reference Citation Analysis]
360 Braat AJ, Huijbregts JE, Molenaar IQ, Borel Rinkes IH, van den Bosch MA, Lam MG. Hepatic radioembolization as a bridge to liver surgery. Front Oncol. 2014;4:199. [PMID: 25126539 DOI: 10.3389/fonc.2014.00199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
361 Braat AJAT, Kappadath SC, Ahmadzadehfar H, Stothers CL, Frilling A, Deroose CM, Flamen P, Brown DB, Sze DY, Mahvash A, Lam MGEH. Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovasc Intervent Radiol 2019;42:413-25. [DOI: 10.1007/s00270-018-2148-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 17.5] [Reference Citation Analysis]
362 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021; 13(3): 231-255 [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
363 Crocetti L, de Baére T, Pereira PL, Tarantino FP. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. Cardiovasc Intervent Radiol 2020;43:951-62. [PMID: 32382856 DOI: 10.1007/s00270-020-02471-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
364 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
365 Anlauf M, Sipos B, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M, Auernhammer CJ, Cremer B, Rinke A, Ezziddin S, Fottner C, Pöpperl G, Lahner H, Hörsch D, Gabbert HE, Komminoth P, Perren A, Klöppel G, Wiedenmann B, Pavel M, Pape U. [Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathologe 2014;35:283-93; quiz 294. [PMID: 24671468 DOI: 10.1007/s00292-013-1888-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
366 de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol. 2016;39:334-343. [PMID: 26390875 DOI: 10.1007/s00270-015-1208-y] [Cited by in Crossref: 110] [Cited by in F6Publishing: 92] [Article Influence: 18.3] [Reference Citation Analysis]
367 Wang S, Zhang J, Liu S, Zhang J. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis. Medicine (Baltimore) 2019;98:e17773. [PMID: 31689842 DOI: 10.1097/MD.0000000000017773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
368 Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, Tajima T, Kasuga A, Fujita Y, Furuse J. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 2012;42:903-11. [PMID: 22859827 DOI: 10.1093/jjco/hys123] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
369 Kong G, Callahan J, Hofman MS, Pattison DA, Akhurst T, Michael M, Eu P, Hicks RJ. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2017;44:476-89. [DOI: 10.1007/s00259-016-3527-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
370 Kamada T, Onda S, Takano Y, Sakamoto T, Kikuchi R, Yanaga K. Multiple liver metastases of pulmonary carcinoid successfully treated by two-stage hepatectomy combined with embolization of portal vein branches: Report of a case. Int J Surg Case Rep 2020;71:319-22. [PMID: 32492643 DOI: 10.1016/j.ijscr.2020.05.043] [Reference Citation Analysis]
371 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
372 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
373 Clift AK, Faiz O, Goldin R, Martin J, Wasan H, Liedke MO, Schloericke E, Malczewska A, Rindi G, Kidd M, Modlin IM, Frilling A. Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocr Connect 2017;6:71-81. [PMID: 28104724 DOI: 10.1530/EC-16-0114] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
374 de Hosson LD, van der Loo–van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH, Walenkamp AME. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clin Nucl Med 2019;44:612-9. [DOI: 10.1097/rlu.0000000000002640] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
375 Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56-68. [PMID: 23391113 DOI: 10.1053/j.seminoncol.2012.11.006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
376 Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH. Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol 2018;18:84. [PMID: 29902988 DOI: 10.1186/s12876-018-0817-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
377 Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 2014;55:1811-7. [PMID: 25315243 DOI: 10.2967/jnumed.114.142224] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
378 Gulpinar B, Peker E, Soydal C, Araz M, Elhan AH. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings. Br J Radiol 2020;93:20190735. [PMID: 31922897 DOI: 10.1259/bjr.20190735] [Reference Citation Analysis]
379 Bagante F, Spolverato G, Merath K, Postlewait LM, Poultsides GA, Mullen MG, Bauer TW, Fields RC, Lamelas J, Marques HP, Aldrighetti L, Tran T, Maithel SK, Pawlik TM. Neuroendocrine liver metastasis: The chance to be cured after liver surgery. J Surg Oncol 2017;115:687-95. [PMID: 28146608 DOI: 10.1002/jso.24563] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
380 Bergsland EK. The Evolving Landscape of Neuroendocrine Tumors. Seminars in Oncology 2013;40:4-22. [DOI: 10.1053/j.seminoncol.2012.11.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
381 Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014;21:2971-80. [PMID: 24752611 DOI: 10.1245/s10434-014-3728-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
382 Mueller D, Krug S, Majumder M, Rinke A, Gress TM. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer 2016;16:645. [PMID: 27538897 DOI: 10.1186/s12885-016-2642-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
383 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Campagnaro T, Ercolani G, Conci S, Giuliante F, Dore A, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Guglielmi A, Iacono C. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. J Gastrointest Surg 2019;23:93-100. [PMID: 30242647 DOI: 10.1007/s11605-018-3973-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
384 杜顺达, 王孜, 毛一雷. 神经内分泌肿瘤肝转移治疗的进展. 世界华人消化杂志 2013; 21(36): 4069-4074 [DOI: 10.11569/wcjd.v21.i36.4069] [Reference Citation Analysis]
385 Hanley KZ, Dureau ZJ, Cohen C, Shin DM, Owonikoko TK, Sica GL. Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. Cancer Cytopathol 2018;126:236-42. [PMID: 29316326 DOI: 10.1002/cncy.21969] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
386 Wong KP, Tsang JS, Lang BH. Role of surgery in pancreatic neuroendocrine tumor. Gland Surg 2018;7:36-41. [PMID: 29629318 DOI: 10.21037/gs.2017.12.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
387 Rashidian N, Alseidi A, Kirks RC. Cancers Metastatic to the Liver. Surg Clin North Am 2020;100:551-63. [PMID: 32402300 DOI: 10.1016/j.suc.2020.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
388 Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855-1863. [PMID: 25918282 DOI: 10.1200/jco.2014.60.2532] [Cited by in Crossref: 88] [Cited by in F6Publishing: 53] [Article Influence: 14.7] [Reference Citation Analysis]
389 Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R;  Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919 DOI: 10.1159/000335591] [Cited by in Crossref: 332] [Cited by in F6Publishing: 241] [Article Influence: 36.9] [Reference Citation Analysis]
390 Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39:1071-1084. [PMID: 24628514 DOI: 10.1111/apt.12698] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
391 Anderberg C, Cunha SI, Zhai Z, Cortez E, Pardali E, Johnson JR, Franco M, Páez-Ribes M, Cordiner R, Fuxe J, Johansson BR, Goumans MJ, Casanovas O, ten Dijke P, Arthur HM, Pietras K. Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. J Exp Med 2013;210:563-79. [PMID: 23401487 DOI: 10.1084/jem.20120662] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis]
392 Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D'Angelica MI, Endo I, Parks RW, Doyle M, de Santibañes E, Pawlik TM. Liver metastases. Nat Rev Dis Primers 2021;7:27. [PMID: 33859205 DOI: 10.1038/s41572-021-00261-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
393 Farrell JM, Pang JC, Kim GE, Tabatabai ZL. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol. 2014;122:770-778. [PMID: 25044931 DOI: 10.1002/cncy.21457] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
394 Musholt TJ, Watzka FM. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems: Chirurgische Therapie. Gastroenterologe 2015;10:410-7. [DOI: 10.1007/s11377-015-0003-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
395 Zagami P, Kandaraki E, Renne G, Grimaldi F, Spada F, Laffi A, Fazio N. The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review. Ecancermedicalscience 2020;14:1123. [PMID: 33209114 DOI: 10.3332/ecancer.2020.1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
396 Shiba S, Morizane C, Hiraoka N, Sasaki M, Koga F, Sakamoto Y, Kondo S, Ueno H, Ikeda M, Yamada T. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients. Pancreatology. 2016;16:99-105. [PMID: 26718527 DOI: 10.1016/j.pan.2015.11.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
397 Kareliotis G, Papachristou M, Priftakis D, Datseris I, Makropoulou M. Computational study of necrotic areas in rat liver tissue treated with photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology 2019;192:40-8. [DOI: 10.1016/j.jphotobiol.2019.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
398 Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology 2018;106:357-65. [PMID: 29320780 DOI: 10.1159/000486096] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
399 Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E. Emerging use of everolimus in the treatment of neuroendocrine tumors. Cancer Manag Res 2017;9:215-24. [PMID: 28684922 DOI: 10.2147/CMAR.S113382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
400 Santhanam P, Chandramahanti S, Kroiss A, Yu R, Ruszniewski P, Kumar R, Taïeb D. Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Eur J Nucl Med Mol Imaging 2015;42:1144-55. [DOI: 10.1007/s00259-015-3027-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
401 Le Treut YP, Gregoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R, For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: A 213-case European liver transplant registry study. Ann Surg. 2013;257:807-815. [PMID: 23532105 DOI: 10.1097/sla.0b013e31828ee17c] [Cited by in Crossref: 127] [Cited by in F6Publishing: 44] [Article Influence: 15.9] [Reference Citation Analysis]
402 Kouri BE, Abrams RA, Al-Refaie WB, Azad N, Farrell J, Gaba RC, Gervais DA, Gipson MG, Kolbeck KJ, Marshalleck FE, Pinchot JW, Small W Jr, Ray CE Jr, Hohenwalter EJ. ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. J Am Coll Radiol 2016;13:265-73. [PMID: 26944037 DOI: 10.1016/j.jacr.2015.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
403 Partelli S, Maurizi A, Tamburrino D, Baldoni A, Polenta V, Crippa S, Falconi M. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171:R153-R162. [PMID: 24920289 DOI: 10.1530/eje-14-0173] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
404 Ge L, Li H, Dong L, Shang G, Wang W, Li Y, Qi L, Zhao J, Peng D, Tong G. Nomogram for predicting survival of patients with metastatic nonfunctioning pancreatic neuroendocrine tumors: A SEER based study. Medicine (Baltimore) 2021;100:e26347. [PMID: 34232169 DOI: 10.1097/MD.0000000000026347] [Reference Citation Analysis]
405 Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015;50:564-572. [PMID: 25142799 DOI: 10.1007/s00535-014-0987-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
406 Spolverato G, Bagante F, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Weiss M, Pawlik TM. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis. J Surg Oncol 2017;116:298-306. [DOI: 10.1002/jso.24670] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
407 Özdirik B, Tacke F, Benz F, Amthauer H, Fehrenbach U, Roderburg C, Jann H. A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. Medicine (Baltimore) 2020;99:e20820. [PMID: 32569231 DOI: 10.1097/MD.0000000000020820] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies? World J Gastroenterol 2017; 23(15): 2640-2650 [PMID: 28487601 DOI: 10.3748/wjg.v23.i15.2640] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
409 Dizdar L, Oesterwind KA, Riemer JC, Werner TA, Mersch S, Möhlendick B, Schütte SC, Verde PE, Raba K, Topp SA, Stoecklein NH, Esposito I, Knoefel WT, Krieg A. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia. Oncotarget 2017;8:8369-82. [PMID: 28039474 DOI: 10.18632/oncotarget.14207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
410 Machairas N, Daskalakis K, Felekouras E, Alexandraki KI, Kaltsas G, Sotiropoulos GC. Currently available treatment options for neuroendocrine liver metastases. Ann Gastroenterol 2021;34:130-41. [PMID: 33654350 DOI: 10.20524/aog.2021.0574] [Reference Citation Analysis]
411 Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med 2020;34:244-53. [PMID: 32114682 DOI: 10.1007/s12149-020-01440-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
412 Pellat A, Coriat R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. J Clin Med. 2020;9. [PMID: 32492939 DOI: 10.3390/jcm9061677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
413 Lv Y, Huang C, Xu H, Han X, Zhang L, Mao W, Ji Y, Jin D, Lou W, Xu X. Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center. J Cancer. 2018;9:479-487. [PMID: 29483952 DOI: 10.7150/jca.22157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
414 Farmer LE, Goradia RU, Lakhi NA. Pitfalls and challenges in managing neuroendocrine carcinoma of gynecological origin: A case series and brief review. Clin Case Rep 2021;9:e04224. [PMID: 34084514 DOI: 10.1002/ccr3.4224] [Reference Citation Analysis]
415 Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135-156. [PMID: 22262080 DOI: 10.1159/000335629] [Cited by in Crossref: 259] [Cited by in F6Publishing: 182] [Article Influence: 28.8] [Reference Citation Analysis]
416 Maekawa A, Kudo A, Kishino M, Murase Y, Watanabe S, Ishikawa Y, Ueda H, Akahoshi K, Ogawa K, Ono H, Tanaka S, Kinowaki Y, Tanabe M. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy. J Cancer Res Clin Oncol 2021. [PMID: 33904982 DOI: 10.1007/s00432-021-03650-2] [Reference Citation Analysis]